Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome (Q33393013)

26 July 2017

title

Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome (English)

1 reference

26 July 2017

Tönshoff B

1

1 reference

26 July 2017

Momper R

2

1 reference

26 July 2017

Kühl PG

3

1 reference

26 July 2017

Schweer H

4

1 reference

26 July 2017

Schärer K

5

1 reference

26 July 2017

Seyberth HW

6

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 April 1990

1 reference

26 July 2017

1 reference

26 July 2017

volume

37

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

1134-1141

1 reference

Presentation, management, complications, and outcome of acute renal failure in childhood: five years' experience

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Intravascular platelet activation in the hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Inhibitor of prostacyclin production in sporadic haemolytic uraemic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Absence of plasma prostacyclin stimulating activity deficiency in hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Prostanoids in hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Determination of peripheral plasma prostanoid concentration: an unreliable index of 'in vivo' prostanoid activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Paired analysis of urinary thromboxane B2 metabolites in humans.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Long-lived enzymatic metabolites of thromboxane B2 in the human circulation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Tandem mass spectrometric determination of 11-dehydrothromboxane B2, an index metabolite of thromboxane B2 in plasma and urine

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Estimated rate of prostacyclin secretion into the circulation of normal man

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Measurement of renal and non-renal eicosanoid synthesis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Haemolytic uraemic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Endotheliotropic (hemolytic) nephroangiopathy and its various manifestation forms (thrombotic microangiopathy, primary malignant nephrosclerosis, hemolytic-uremic syndrome).

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Urinary excretion rates of 6-keto-PGF1 alpha in preterm infants recovering from respiratory distress with and without patent ductus arteriosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Improved sample preparation for the quantitative mass spectrometric determination of prostaglandins in biological samples

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Quantitative analysis of two dinor urinary metabolites of prostaglandin I2

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography--negative-ion chemical ionization mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

THE HEMOLYTIC-UREMIC SYNDROME.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Platelet, erythrocyte, and fibrinogen kinetics in the hemolytic-uremic syndrome of infancy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Estimated rate of thromboxane secretion into the circulation of normal humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Prostacyclin is not a circulating hormone in man

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Platelet activation in unstable coronary disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Abnormalities of factor VIII related protein multimers in the haemolytic uraemic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Aspirin and dipyridamole therapy in the hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

HUS and TTP: variable expression of a single entity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1990.96

7 January 2021

Identifiers

DOI

10.1038/KI.1990.96

1 reference

Dimensions Publication ID

26 July 2017

1010724908

0 references

1 reference